Received Nov 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | FT95N | — |
Use of an Unapproved Diluent; Use of an Unapproved Diluent; This non-serious case was reported by a other health professional via call center representative and described the occurrence of wrong solution used in drug reconstitution in a 54-year-old female patient who received Herpes zoster (Shingrix) (batch number FT95N, expiry date 25-APR-2027) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced wrong solution used in drug reconstitution (Verbatim: Use of an Unapproved Diluent) and inappropriate dose of vaccine administered (Verbatim: Use of an Unapproved Diluent). The outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 13-NOV-2025 The reporter reported that they administered Shingrix to a patient reconstituted with another diluent instead of the adjuvant portion that comes with Shingrix. The reporter was ask did the patient have to come back to be revaccinated.